DE60114830D1 - Verfahren für die herstellung modifizierter glykoproteine - Google Patents

Verfahren für die herstellung modifizierter glykoproteine

Info

Publication number
DE60114830D1
DE60114830D1 DE60114830T DE60114830T DE60114830D1 DE 60114830 D1 DE60114830 D1 DE 60114830D1 DE 60114830 T DE60114830 T DE 60114830T DE 60114830 T DE60114830 T DE 60114830T DE 60114830 D1 DE60114830 D1 DE 60114830D1
Authority
DE
Germany
Prior art keywords
glycoproteins
human
produce
glycans
fungi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60114830T
Other languages
English (en)
Other versions
DE60114830T2 (de
Inventor
U Gerngross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycofi Inc
Original Assignee
Glycofi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27395978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60114830(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glycofi Inc filed Critical Glycofi Inc
Publication of DE60114830D1 publication Critical patent/DE60114830D1/de
Application granted granted Critical
Publication of DE60114830T2 publication Critical patent/DE60114830T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01113—Mannosyl-oligosaccharide 1,2-alpha-mannosidase (3.2.1.113), i.e. alpha-1,2-mannosidase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/05—Fusion polypeptide containing a localisation/targetting motif containing a GOLGI retention signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
DE60114830T 2000-06-28 2001-06-27 Verfahren zur herstellung modifizierter glycoproteine Revoked DE60114830T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21435800P 2000-06-28 2000-06-28
US214358P 2000-06-28
US21563800P 2000-06-30 2000-06-30
US215638P 2000-06-30
US27999701P 2001-03-30 2001-03-30
US279997P 2001-03-30
PCT/US2001/020553 WO2002000879A2 (en) 2000-06-28 2001-06-27 Methods for producing modified glycoproteins

Publications (2)

Publication Number Publication Date
DE60114830D1 true DE60114830D1 (de) 2005-12-15
DE60114830T2 DE60114830T2 (de) 2006-08-03

Family

ID=27395978

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60139720T Expired - Lifetime DE60139720D1 (de) 2000-06-28 2001-06-27 Verfahren für die Herstellung modifizierter Glykoproteine
DE60114830T Revoked DE60114830T2 (de) 2000-06-28 2001-06-27 Verfahren zur herstellung modifizierter glycoproteine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60139720T Expired - Lifetime DE60139720D1 (de) 2000-06-28 2001-06-27 Verfahren für die Herstellung modifizierter Glykoproteine

Country Status (15)

Country Link
US (13) US7029872B2 (de)
EP (5) EP2322644A1 (de)
JP (2) JP2004501642A (de)
KR (1) KR100787073B1 (de)
AT (2) ATE309385T1 (de)
AU (2) AU7684201A (de)
CA (1) CA2412701A1 (de)
CY (1) CY1109639T1 (de)
DE (2) DE60139720D1 (de)
DK (2) DK1297172T3 (de)
ES (2) ES2252261T3 (de)
MX (1) MXPA03000105A (de)
NZ (1) NZ523476A (de)
PT (1) PT1522590E (de)
WO (1) WO2002000879A2 (de)

Families Citing this family (469)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
ATE475714T1 (de) 1998-12-09 2010-08-15 Phyton Holdings Llc Verfahren zur herstellung von glycoprotein mit menschlichem glycosylierungsbild
PT1772518E (pt) 1999-10-26 2010-10-28 Stichting Dienst Landbouwkundi Glicosilação do tipo mamífero em plantas
DK1283265T3 (da) * 2000-05-17 2009-11-09 Mitsubishi Tanabe Pharma Corp Fremgangsmåde til fremstilling af protein med reduktion af mannosephosphat i sukkerkæden og glycoprotein fremstillet derved
US20060034828A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US7863020B2 (en) * 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US20060034830A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060029604A1 (en) * 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US20060024304A1 (en) * 2000-06-28 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US8697394B2 (en) 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
EP2322644A1 (de) 2000-06-28 2011-05-18 GlycoFi, Inc. Verfahren für die Herstellung modifizierter Glykoproteine
JP4092194B2 (ja) * 2000-06-30 2008-05-28 フランダース インターユニバーシティ インスティテュート フォア バイオテクノロジー （ヴィーアイビー） ピキアパストリス（ＰｉｃｈｉａＰａｓｔｏｒｉｓ）におけるタンパク質糖鎖修飾
WO2002051438A2 (en) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
EP1356068B1 (de) 2001-01-19 2014-10-29 Phyton Holdings, LLC Verfahren zur sekretorischen herstellung von glykoproteinen mit einer menschenähnlichen zuckerkette unter verwendung einer pflanzenzelle
TWI324181B (en) 2001-04-16 2010-05-01 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
ES2606840T3 (es) * 2001-10-10 2017-03-28 Ratiopharm Gmbh Remodelación y glicoconjugación de factor estimulante de colonias de granulocitos (G-CSF)
US7297511B2 (en) * 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7265085B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
DK2279755T3 (da) 2001-10-10 2014-05-26 Ratiopharm Gmbh Remodellering og glycokonjugering af fibroblastvækstfaktor (FGF)
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7439043B2 (en) * 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7473680B2 (en) * 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
ES2402527T3 (es) 2001-12-27 2013-05-06 Glycofi, Inc. Procedimientos para obtener estructuras de carbohidrato de tipo mamífero mediante ingeniería genética
US20060034829A1 (en) * 2001-12-27 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
US20060024292A1 (en) * 2001-12-27 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
US6964784B2 (en) * 2002-03-07 2005-11-15 Optigenex, Inc. Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
KR101228276B1 (ko) 2002-03-19 2013-01-30 스티칭 디엔스트 랜드보위쿤디그 온데조에크 식물에서 글리칸 프로세싱의 최적화
US7897842B2 (en) 2002-03-19 2011-03-01 Plant Research International B.V. GnTIII expression in plants
WO2003091431A1 (fr) * 2002-04-26 2003-11-06 Kirin Beer Kabushiki Kaisha Methylotrophe produisant une chaine de sucre de type mammifere
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
US7252933B2 (en) * 2002-06-26 2007-08-07 Flanders Interuniversity Institute For Biotechnology Protein glycosylation modification in methylotrophic yeast
AU2003246286A1 (en) * 2002-06-29 2004-01-19 Korea Research Institute Of Bioscience And Biotechnology Hansenula polymorpha mutant strains with defect in outer chain biosynthesis and the production of recombinant glycoproteins using the same strains
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
AR042145A1 (es) 2002-11-27 2005-06-08 Dow Agrociences Llc Produccion de inmunoglobulinas en plantas con una fucocilacion reducida
PL222222B1 (pl) 2003-01-22 2016-07-29 Glycart Biotechnology Ag Sposób wytwarzania polipeptydu
RU2407796C2 (ru) * 2003-01-22 2010-12-27 Гликарт Биотекнолоджи АГ КОНСТРУКЦИИ СЛИЯНИЯ И ИХ ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ АНТИТЕЛ С ПОВЫШЕННЫМИ АФФИННОСТЬЮ СВЯЗЫВАНИЯ Fc-РЕЦЕПТОРА И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2012227297B2 (en) * 2003-02-20 2013-11-14 Glycofi, Inc. Combinatorial DNA Library for Producing Modified N-Glycans in Lower Eukaryotes
US7332299B2 (en) * 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
CA2519092C (en) 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP1613261A4 (de) * 2003-04-09 2011-01-26 Novo Nordisk As Intrazelluläre bildung von peptidkonjugaten
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
BRPI0410164A (pt) 2003-05-09 2006-05-16 Neose Technologies Inc composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
WO2005042753A1 (en) * 2003-10-28 2005-05-12 Chesapeake Perl, Inc. Production of human glycosylated proteins in transgenic insects
US9357755B2 (en) * 2003-10-28 2016-06-07 The University Of Wyoming Production of human glycosylated proteins in silk worm
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7507573B2 (en) * 2003-11-14 2009-03-24 Vib, Vzw Modification of protein glycosylation in methylotrophic yeast
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
ES2445948T3 (es) * 2003-11-24 2014-03-06 Ratiopharm Gmbh Eritropoyetina glicopegilada
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
ES2528739T3 (es) * 2003-12-24 2015-02-12 Glycofi, Inc. Métodos para eliminar la manosilfosforilación de glucanos en la producción de glucoproteínas
ES2560657T3 (es) 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
KR100604994B1 (ko) * 2004-01-30 2006-07-26 한국생명공학연구원 알파1,6-만노실트랜스퍼라제를 코딩하는 한세눌라폴리모르파 기원의 신규 유전자 및 상기 유전자가 결손된한세눌라 폴리모르파 변이주를 이용한 재조합 당단백질생산 방법
WO2005090552A2 (en) * 2004-03-17 2005-09-29 Glycofi, Inc. Method of engineering a cytidine monophosphate-sialic acid synthetic pathway in fungi and yeast
US20050265988A1 (en) * 2004-03-18 2005-12-01 Byung-Kwon Choi Glycosylated glucocerebrosidase expression in fungal hosts
CN104611245A (zh) * 2004-04-15 2015-05-13 格利科菲公司 在低等真核生物中产生半乳糖基化糖蛋白
JP5752582B2 (ja) * 2004-04-29 2015-07-22 グライコフィ， インコーポレイテッド 糖タンパク質の作製においてアルファ−マンノシダーゼ抵抗性グリカンを減少させるか又は排除する方法
CN101084233B (zh) * 2004-04-29 2012-08-15 格利科菲公司 用于在糖蛋白产生中减少或消除α-甘露糖苷酶抗性聚糖的方法
CA2565414A1 (en) * 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006014725A1 (en) * 2004-07-21 2006-02-09 Glycofi, Inc. IMMUNOGLOBULINS COMPRISING PREDOMINANTLY A GlcNAcMAN5GLCNAC2 GLYCOFORM
WO2006026992A1 (en) * 2004-09-07 2006-03-16 Novozymes A/S Altered structure of n-glycans in a fungus
EP1799249A2 (de) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegyliertes interferon alpha
WO2006035057A1 (en) * 2004-09-29 2006-04-06 Novo Nordisk Health Care Ag Modified proteins
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
WO2006071856A2 (en) * 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
AU2006221184B2 (en) * 2005-03-07 2011-03-24 Stichting Dienst Landbouwkundig Onderzoek Glycoengineering in mushrooms
US20060246544A1 (en) * 2005-03-30 2006-11-02 Neose Technologies,Inc. Manufacturing process for the production of peptides grown in insect cell lines
US20070154992A1 (en) * 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1888098A2 (de) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glykopegylierte erythropoetin-formulierungen
NZ596992A (en) * 2005-06-30 2013-07-26 Abbott Lab Il-12/p40 binding proteins
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
EP2500358A3 (de) 2005-08-19 2012-10-17 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
BRPI0614839A2 (pt) * 2005-08-19 2009-05-19 Neose Technologies Inc fator vii e fator viia glicopeguilados
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
JP2009507040A (ja) * 2005-09-02 2009-02-19 グライコフィ， インコーポレイテッド 主としてｇｌｃｎａｃｍａｎ３ｇｌｃｎａｃ２糖形態を含む免疫グロブリン
AU2005336263A1 (en) * 2005-09-09 2007-03-15 Glycofi, Inc. Immunoglobulin comprising predominantly a man7GlcNAc2, Man8GlcNAc2 glycoform
JP2009509970A (ja) * 2005-09-22 2009-03-12 プロサイ インコーポレイテッド 酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
KR101105718B1 (ko) * 2005-10-27 2012-01-17 한국생명공학연구원 돌리칠 포스페이트 만노스 의존알파-1,3-만노실트랜스퍼라제를 코딩하는 한세눌라폴리모르파 기원의 신규 유전자와 상기 유전자가 결손된한세눌라 폴리모르파 변이주를 이용한 재조합 당단백질생산 방법
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
AU2006316838B2 (en) 2005-11-15 2012-04-12 Glycofi, Inc Production of glycoproteins with reduced O-glycosylation
EP1954718B1 (de) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a-globulomer-antikörper, antigen bindende gruppen davon, entsprechende hybridome, nukleinsäuren, vektoren, wirtszellen, verfahren zur herstellung dieser antikörper, zusammensetzungen, die diese antikörper enthalten, verwendungen dieser antikörper und verfahren zur verwendung dieser antikörper
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
US20090060921A1 (en) * 2006-01-17 2009-03-05 Biolex Therapeutics, Inc. Glycan-optimized anti-cd20 antibodies
BRPI0707290A2 (pt) * 2006-01-17 2011-08-16 Biolex Therapeutics Inc composições e métodos para humanização e otimização de n-glicanas em plantas
US20090181041A1 (en) * 2006-01-23 2009-07-16 Jan Holgersson Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
EP2781524A1 (de) * 2006-01-26 2014-09-24 Recopharma AB Zusammensetzung und Verfahren zur Bekämpfung von viralen Infektionen
WO2007123801A1 (en) * 2006-04-05 2007-11-01 Genencor International, Inc. Filamentous fungi having reduced udp-galactofuranose content
BRPI0710482A2 (pt) * 2006-04-21 2011-08-16 Wyeth Corp métodos para seleção de alto rendimento de linhagens celulares
US7851438B2 (en) * 2006-05-19 2010-12-14 GlycoFi, Incorporated Erythropoietin compositions
CA2651456A1 (en) * 2006-05-19 2007-11-29 Glycofi, Inc. Recombinant vectors
ES2368267T3 (es) * 2006-05-24 2011-11-15 Universite De Provence (Aix-Marseille 1) Preparación y utilizaciones de las secuencias génicas codificantes de las glucosiltransferasas quiméricas con actividad de glucosilación optimizada.
AR078117A1 (es) 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US7879799B2 (en) * 2006-08-10 2011-02-01 Institute For Systems Biology Methods for characterizing glycoproteins and generating antibodies for same
CA2914170C (en) 2006-09-08 2018-10-30 Abbvie Bahamas Ltd. Interleukin-13 binding proteins
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
WO2008063776A2 (en) * 2006-10-12 2008-05-29 Genentech, Inc. Antibodies to lymphotoxin-alpha
EP1916259A1 (de) 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-Glycoprotein VI SCFV Fragment zur Thrombosebehandlung
US20080207487A1 (en) * 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
FR2912154B1 (fr) 2007-02-02 2012-11-02 Glycode Levures genetiquement modifiees pour la production de glycoproteines homogenes
ES2545775T3 (es) 2007-02-05 2015-09-15 Apellis Pharmaceuticals, Inc. Análogos de compstatina para uso en el tratamiento de afecciones inflamatorias del sistema respiratorio
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
SG187521A1 (en) 2007-03-07 2013-02-28 Glycofi Inc Production of glycoproteins with modified fucosylation
PL3199180T3 (pl) 2007-03-08 2022-08-08 Humanigen, Inc. Przeciwciała przeciwko epha3 do leczenia guzów litych
KR101605908B1 (ko) 2007-03-22 2016-03-23 바이오젠 엠에이 인코포레이티드 Ｃｄ154에 특이적으로 결합하는, 항체, 항체 유도체 및 항체 단편을 포함하는 결합 단백질, 및 그의 용도
CN104480140B (zh) 2007-04-03 2019-12-31 奥克西雷恩英国有限公司 分子的糖基化
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
US20080256056A1 (en) * 2007-04-10 2008-10-16 Yahoo! Inc. System for building a data structure representing a network of users and advertisers
MX341988B (es) 2007-04-17 2016-09-08 Stichting Dienst Landbouwkunding Onderzoek Glicosilacion tipo mamifera en plantas para la expresion de glicosil-transferasas no mamiferas.
EP2068925A4 (de) 2007-05-07 2011-08-31 Medimmune Llc Anti-icos-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
ES2558689T3 (es) 2007-05-14 2016-02-08 Medimmune, Llc Métodos para reducir los niveles de eosinófilos
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US8637435B2 (en) * 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
EP2235198B1 (de) 2007-12-19 2018-08-29 GlycoFi, Inc. Hefestämme für die Proteinproduktion
DK2240595T4 (da) * 2008-01-03 2019-10-07 Cornell Res Foundation Inc Glykosyleret proteinekspression i prokaryoter
US20100311122A1 (en) * 2008-02-20 2010-12-09 Glycofi, Inc Vectors and yeast strains for protein production
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2009111183A1 (en) 2008-03-03 2009-09-11 Glycofi, Inc. Surface display of recombinant proteins in lower eukaryotes
AU2009223054A1 (en) * 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced ADCC function
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2383292A1 (de) 2008-05-02 2011-11-02 Novartis AG Verbesserte Bindemoleküle auf Fibronectin-Basis und ihre Verwendung
SG188142A1 (en) 2008-05-09 2013-03-28 Abbott Gmbh & Co Kg Antibodies to receptor of advanced glycation end products (rage) and uses thereof
AU2009251328B2 (en) 2008-05-30 2014-10-02 Glycofi, Inc. Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose
CN102112494A (zh) 2008-06-03 2011-06-29 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
AR072001A1 (es) 2008-06-03 2010-07-28 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
TW201014602A (en) 2008-07-08 2010-04-16 Abbott Lab Prostaglandin E2 binding proteins and uses thereof
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
DK2331701T3 (da) 2008-08-08 2013-06-24 Vib Vzw Celler, der danner glycoproteiner med ændrede glycosyleringsmønstre og fremgangsmåder dermed og anvendelse deraf
MX2011001706A (es) 2008-08-12 2011-03-24 Glycofi Inc Vectores mejorados y cepas de levadura para produccion de proteina: sobreexpresion de ca2+ atpasa.
JP2012503491A (ja) 2008-09-25 2012-02-09 グリコシン インコーポレイテッド プロバイオティック酵母を操作するための組成物および方法
JP5652206B2 (ja) 2008-10-01 2015-01-14 旭硝子株式会社 宿主、形質転換体およびその製造方法、ならびにｏ−グリコシド型糖鎖含有異種蛋白質の製造方法
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
RU2011127198A (ru) * 2008-12-04 2013-01-10 Эбботт Лэборетриз Иммуноглобулины с двойными вариабельными доменами и их применение
US9103821B2 (en) 2008-12-19 2015-08-11 Momenta Pharmaceuticals, Inc. Methods related to modified glycans
BRPI0923433B1 (pt) 2008-12-19 2021-06-01 Jennewein Biotechnologie Gmbh Método para produzir uma célula geneticamente modificada tendo a capacidade de produzir compostos fucosilados e método para fazer um composto fucosilado
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
CA2749966A1 (en) * 2009-01-29 2010-08-05 Abbott Laboratories Il-1 binding proteins
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
US20120003695A1 (en) 2009-02-25 2012-01-05 Davidson Robert C Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
JP5836807B2 (ja) 2009-03-05 2015-12-24 アッヴィ・インコーポレイテッド Ｉｌ−１７結合タンパク質
CN102405237A (zh) 2009-03-06 2012-04-04 卡罗拜奥斯制药公司 利用EphA3抗体治疗白血病和慢性骨髓增生性疾病
US8283162B2 (en) 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
AU2010225930B2 (en) 2009-03-16 2017-01-12 Dsm Ip Assets B.V. Protein production in microorganisms of the phylum Labyrinthulomycota
NZ600915A (en) * 2009-03-16 2013-09-27 Cephalon Australia Pty Ltd Humanised antibodies with anti-tumour activity
EP2424894A1 (de) 2009-04-27 2012-03-07 Novartis AG Zusammensetzungen und verfahhren zur anwendung von für die beta1-untereinheit des il-12-rezeptors spezifischen antikörpern
CA2993053A1 (en) 2009-04-27 2010-11-04 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
US20120329709A1 (en) * 2009-05-26 2012-12-27 Brian Edward Collins Production of glycoproteins
US8815242B2 (en) * 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
WO2011011495A1 (en) * 2009-07-24 2011-01-27 Merck Sharp & Dohme Corp. Recombinant ectodomain expression of herpes simplex virus glycoproteins in yeast
CN105131112A (zh) 2009-08-29 2015-12-09 Abbvie公司 治疗用dll4结合蛋白
EP2473524A4 (de) 2009-09-01 2013-05-22 Abbott Lab Immunglobuline mit zweifacher variabler domäne und ihre verwendung
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
US9598682B2 (en) 2009-09-29 2017-03-21 Vib Vzw Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
JP2013508292A (ja) 2009-10-14 2013-03-07 カロバイオス ファーマシューティカルズ インコーポレイティッド ＥｐｈＡ３に対する抗体
EP2488658A4 (de) 2009-10-15 2013-06-19 Abbvie Inc Immunglobuline mit zweifacher variabler domäne und ihre verwendung
EP2488657B1 (de) 2009-10-16 2016-07-06 Merck Sharp & Dohme Corp. Verfahren zur herstellung von proteinen in pichia pastoris ohne erkennbare vernetzungsaktivität mit antikörpern gegen wirtszellen-antigene
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN102725396A (zh) 2009-10-30 2012-10-10 默沙东公司 在缺乏二肽基氨肽酶活性的巴斯德毕赤酵母中生产治疗性蛋白的方法
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011053545A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Granulocyte-colony stimulating factor produced in glycoengineered pichia pastoris
JP2013509180A (ja) 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション 改善された分泌効率を有する組換えタンパク質の産生方法
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
US8932588B2 (en) 2009-11-05 2015-01-13 Teva Pharmaceuticals Australia Pty. Ltd. Treatment of cancer involving mutated KRAS or BRAF genes
EP2501805B1 (de) 2009-11-19 2019-02-20 Oxyrane UK Limited Hefe stämme die säugetier-ähnliche n-glykane produzieren
EP2507267B1 (de) 2009-12-02 2016-09-14 Acceleron Pharma, Inc. Zusammensetzungen und verfahren zur erhöhung der serumshaltbarkeit von fc-fusionsproteinen
MX2012006560A (es) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
TW201130511A (en) 2009-12-22 2011-09-16 Novartis Ag Soluble proteins for use as therapeutics
IN2012DN06277A (de) * 2009-12-28 2015-09-25 Dsm Ip Assets Bv
CN103068984B (zh) * 2009-12-28 2017-12-01 Dsm Ip资产公司 微藻中血凝素‑神经氨酸酶蛋白的生产
ES2651313T3 (es) * 2009-12-28 2018-01-25 Dsm Ip Assets B.V. Traustoquítridos recombinantes que crecen en xilosa, y composiciones, métodos de preparación y usos de los mismos
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
MX2012009802A (es) 2010-02-24 2012-09-12 Merck Sharp & Dohme Metodo para incrementar la ocupacion del sitio de n-glucosilacion en glucoproteinas terapeuticas producidas en pichia pastoris.
MY160628A (en) 2010-03-02 2017-03-15 Abbvie Inc Therapeutic DLL4 Binding Proteins
MX2012011648A (es) 2010-04-07 2012-11-29 Momenta Pharmaceuticals Inc Glicanos de alta manosa.
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
JP6066900B2 (ja) 2010-04-26 2017-01-25 エータイアー ファーマ， インコーポレイテッド システイニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011248614B2 (en) 2010-04-27 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
CA2797271C (en) 2010-04-28 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
WO2011139854A2 (en) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
EP2563383B1 (de) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
CN103140233B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
CA2797277C (en) 2010-05-03 2021-02-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
CN102985103A (zh) 2010-05-04 2013-03-20 Atyr医药公司 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
PE20130205A1 (es) 2010-05-14 2013-03-24 Abbvie Inc Proteinas de union a il-1
JP6396656B2 (ja) 2010-05-14 2018-09-26 エータイアー ファーマ， インコーポレイテッド フェニルアラニルβｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN103096913B (zh) 2010-05-27 2017-07-18 Atyr 医药公司 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
BR112012030179A8 (pt) 2010-05-27 2023-03-14 Merck Sharp & Dohme Polipeptídeo contendo fc
AU2011261486B2 (en) 2010-06-01 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP6116479B2 (ja) 2010-07-12 2017-04-19 エータイアー ファーマ， インコーポレイテッド グリシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
CA2806148A1 (en) * 2010-07-30 2012-02-02 Glycode A yeast artificial chromosome carrying the mammalian glycosylation pathway
EP3252072A3 (de) 2010-08-03 2018-03-14 AbbVie Inc. Immunglobuline mit zweifacher variabler domäne und verwendungen davon
US20130177555A1 (en) 2010-08-13 2013-07-11 Medimmune Limited Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use
EP2603524A1 (de) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta-bindende proteine
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
EP2606067B1 (de) 2010-08-19 2018-02-21 Zoetis Belgium S.A. Anti-ngf-antikörper und ihre verwendung
WO2012027611A2 (en) 2010-08-25 2012-03-01 Atyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
KR20130139884A (ko) 2010-08-26 2013-12-23 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
WO2012042386A2 (en) 2010-09-29 2012-04-05 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
KR101979220B1 (ko) 2010-09-29 2019-05-16 옥시레인 유케이 리미티드 인산화된 n-글리칸들의 탈-만노실화
CN103154037A (zh) 2010-10-05 2013-06-12 诺瓦提斯公司 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
CN103534392A (zh) 2010-12-01 2014-01-22 默沙东公司 表面锚定的fc-诱饵抗体展示系统
US9458240B2 (en) 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
SG191312A1 (en) 2010-12-21 2013-07-31 Abbvie Inc Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
RU2620065C2 (ru) 2011-02-08 2017-05-22 МЕДИММЬЮН, ЭлЭлСи Антитела, которые специфично связывают альфа-токсин staphylococcus aureus, и способы их применения
CA2827732A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Yeast strain for the production of proteins with modified o-glycosylation
EP2686671A4 (de) 2011-03-12 2015-06-24 Momenta Pharmaceuticals Inc N-acetylhexosamin-haltige n-glykane in glycoproteinprodukten
EP2895592A1 (de) 2011-03-23 2015-07-22 Société Industrielle Limousine d'Application Biologique (SILAB) Rekombinante hefezelle zur produktion von gdp-fucose
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9346883B2 (en) 2011-05-13 2016-05-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies against HER3
KR20140028013A (ko) 2011-05-25 2014-03-07 머크 샤프 앤드 돔 코포레이션 개선된 특성을 갖는 Fc-함유 폴리펩티드를 제조하는 방법
AU2012269929A1 (en) 2011-06-16 2013-12-12 Novartis Ag Soluble proteins for use as therapeutics
JP6120833B2 (ja) 2011-06-22 2017-04-26 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
US9249228B2 (en) 2011-06-22 2016-02-02 Oribase Pharma Anti-Axl antibodies and uses thereof
EP2726099B1 (de) 2011-07-01 2018-07-25 Novartis AG Verfahren zur behandlung von stoffwechselstörungen
WO2013009521A2 (en) 2011-07-13 2013-01-17 Abbvie Inc. Methods and compositions for treating asthma using anti-il-13 antibodies
KR20140062469A (ko) 2011-07-20 2014-05-23 젭테온 인코포레이티드 폴리펩티드 분리 방법
JP5800160B2 (ja) * 2011-10-03 2015-10-28 国立研究開発法人産業技術総合研究所 複合型糖鎖加水分解酵素
CA2853357A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against tnf
UY34411A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoenlazantes dirigidos contra esclerostina
KR102037541B1 (ko) 2011-10-28 2019-10-29 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
AU2012329091A1 (en) 2011-10-28 2014-05-01 Merck Sharp & Dohme Corp. Engineered lower eukaryotic host strains for recombinant protein expression
EP2780462A4 (de) * 2011-10-31 2015-04-29 Merck Sharp & Dohme Manipulierte pichia-stämme mit verbesserter fermentationsausbeute und n-glykosylierungs-qualität
CN103906533A (zh) 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
KR101457514B1 (ko) 2011-11-21 2014-11-03 한국생명공학연구원 우렁쉥이(멍게) 유래의 시알산 전이효소 및 이를 이용한 시알화 복합당질 합성 방법
CN104114183A (zh) 2011-12-20 2014-10-22 印第安纳大学研究及科技有限公司 用于治疗糖尿病的基于ctp的胰岛素类似物
CN104159920A (zh) 2011-12-30 2014-11-19 艾伯维公司 针对il-13和/或il-17的双重可变结构域免疫球蛋白
EP2617732A1 (de) 2012-01-19 2013-07-24 Vib Vzw Werkzeuge und Verfahren zur Expression von Membranproteinen
RS57603B1 (sr) 2012-01-27 2018-11-30 Abbvie Deutschland Sastav i metod za dijagnozu i tretiranje bolesti povezanih sa degeneracijom neurita
WO2013123432A2 (en) 2012-02-16 2013-08-22 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
JP6194324B2 (ja) 2012-03-15 2017-09-06 オキシレイン ユーケー リミテッド ポンペ病の処置のための方法および材料
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013169609A1 (en) 2012-05-11 2013-11-14 Merck Sharp & Dohme Corp. Surface anchored light chain bait antibody display system
EP2852610B1 (de) 2012-05-23 2018-07-11 Glykos Finland Oy Herstellung von fucosylierten glykoproteinen
US9695244B2 (en) 2012-06-01 2017-07-04 Momenta Pharmaceuticals, Inc. Methods related to denosumab
WO2013184871A1 (en) 2012-06-06 2013-12-12 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
WO2014011955A2 (en) 2012-07-12 2014-01-16 Abbvie, Inc. Il-1 binding proteins
EA201590237A1 (ru) 2012-07-18 2015-05-29 Гликотоп Гмбх Новые способы лечения антителами против her2 с низкой степенью фукозилирования
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US20150275222A1 (en) 2012-10-22 2015-10-01 Bo Jiang Crz1 mutant fungal cells
PT2912162T (pt) 2012-10-23 2018-02-15 Research Corporation Tech Inc Estirpes de pichia pastoris para produzir estruturas de glicano predominantemente homogéneas
EP2911681A1 (de) 2012-10-26 2015-09-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Lyve-1-antagonisten zur vorbeugung oder behandlung eines pathologischen leidens in zusammenhang mit lymphangiogenese
KR20180008921A (ko) 2012-11-01 2018-01-24 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
EP2733153A1 (de) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur Herstellung von Immunkonjugaten und Verwendungen davon
EP2925345B1 (de) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Methode zur herstellung von o-glycosyliertem carboxyterminus-peptid (ctp)-basiertem insulin und insulinanaloga
US9764006B2 (en) 2012-12-10 2017-09-19 The General Hospital Corporation Bivalent IL-2 fusion toxins
WO2014090948A1 (en) 2012-12-13 2014-06-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Serpin spn4a and biologically active derivatives thereof for use in the treatment of cancer
EP3514175A1 (de) 2012-12-17 2019-07-24 Laboratoire Français du Fractionnement et des Biotechnologies Einsatz von monoklonalen antikörpern für die behandlung von bakteriellen entzündungen und infektionen
CN105228650B (zh) 2012-12-18 2018-11-16 美国洛克菲勒大学 用于hiv预防和治疗的聚糖修饰的抗-cd4抗体
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
US9458244B2 (en) 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
EP2938637A2 (de) 2012-12-28 2015-11-04 AbbVie Inc. Proteinzusammensetzungen mit multivalenter bindung
CA2898415A1 (en) 2013-01-16 2014-07-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
EP2948177A1 (de) 2013-01-22 2015-12-02 AbbVie Inc. Verfahren zur optimierung der domänenstabilität von bindungsproteinen
CA2897682C (en) 2013-02-08 2023-03-14 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
WO2014126921A1 (en) 2013-02-12 2014-08-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that neutralize norovirus
ES2755181T3 (es) 2013-02-13 2020-04-21 Lab Francais Du Fractionnement Anticuerpos anti-TNF-alfa altamente galactosilados y usos de los mismos
WO2014138188A1 (en) 2013-03-07 2014-09-12 The General Hospital Corporation Human ctla4 mutants and use thereof
EP2830651A4 (de) 2013-03-12 2015-09-02 Abbvie Inc An humanes tnf-alpha bindende humane antikörper und verfahren zur herstellung davon
CN105473604B (zh) 2013-03-13 2021-01-22 美国政府(由卫生和人类服务部的部长所代表) 融合前rsv f蛋白和其用途
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
BR112015023355A8 (pt) 2013-03-14 2018-01-30 Abbott Lab antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
MX2015012825A (es) 2013-03-14 2016-06-10 Abbott Lab Anticuerpos monoclonales del dominio de union de lipido del núcleo del virus de la hepatitis c vhc.
CA2906421C (en) 2013-03-14 2022-08-16 George J. Dawson Hcv antigen-antibody combination assay and methods and compositions for use therein
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
EP2855533A4 (de) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc Verfahren in zusammenhang mit ctla4-fc-fusionsproteinen
CN105229030A (zh) 2013-04-22 2016-01-06 葛莱高托普有限公司 用具有低岩藻糖基化的抗-egfr抗体的抗-癌治疗
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
PT2992013T (pt) 2013-04-29 2020-03-05 Teva Pharmaceuticals Australia Pty Ltd Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado
US10000556B2 (en) 2013-05-09 2018-06-19 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Single-domain VHH antibodies directed to norovirus GI.1 and GII.4 and their use
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
SG10201801063TA (en) 2013-08-14 2018-04-27 Novartis Ag Methods of treating sporadic inclusion body myositis
AU2014317092B2 (en) 2013-09-05 2018-02-08 Universiteit Gent Cells producing Fc containing molecules having altered glycosylation patterns and methods and use thereof
WO2015044379A1 (en) 2013-09-27 2015-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A dyrk1a polypeptide for use in preventing or treating metabolic disorders
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
CN113667012A (zh) 2013-10-02 2021-11-19 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015066550A1 (en) 2013-10-31 2015-05-07 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
WO2015067986A1 (en) 2013-11-07 2015-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuregulin allosteric anti-her3 antibody
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
FR3016633B1 (fr) 2014-01-17 2018-04-13 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Immunoglobuline anti-toxine du charbon
EP3495482B1 (de) 2014-01-21 2020-09-02 Synplogen Co., Ltd. Verfahren zur vorbereitung einer dna-einheit-zusammensetzung und verfahren zur erzeugung von verketteter dna
KR20220025946A (ko) 2014-03-21 2022-03-03 애브비 인코포레이티드 항-ｅｇｆｒ 항체 및 항체 약물 접합체
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
JP6837434B2 (ja) 2014-07-15 2021-03-03 メディミューン，エルエルシー 抗ｂ型インフルエンザ抗体の中和及びその使用
US10513724B2 (en) 2014-07-21 2019-12-24 Glykos Finland Oy Production of glycoproteins with mammalian-like N-glycans in filamentous fungi
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
AP2017009765A0 (en) 2014-08-19 2017-02-28 Merck Sharp & Dohme Anti-tigit antibodies
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
RU2021125449A (ru) 2014-10-01 2021-09-16 Медиммьюн Лимитед Антитела к тикагрелору и способы применения
EA037749B1 (ru) 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
EP3217807A4 (de) 2014-11-11 2018-09-12 Clara Foods Co. Verfahren und zusammensetzungen zur herstellung von eiweissproteinen
US10072070B2 (en) 2014-12-05 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Potent anti-influenza A neuraminidase subtype N1 antibody
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3091033A1 (de) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3-antikörper und verwendungen davon
MY189692A (en) 2015-05-07 2022-02-26 Memorial Sloan Kettering Cancer Center Anti-ox40 antibodies and methods of use thereof
WO2016188911A1 (en) 2015-05-22 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
JP6518917B2 (ja) 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド 抗ｃｄ４０抗体およびその使用
PT3303384T (pt) 2015-06-01 2021-10-14 Medimmune Llc Moléculas de ligação neutralizantes anti-influenza e suas utilizações
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
DK3320105T3 (da) 2015-07-09 2021-06-07 Vib Vzw Celler, der producerer glycoproteiner med ændrede o- og o-glycosyleringsmønstre, samt tilhørende fremgangsmåder og anvendelse
JP2018535655A (ja) 2015-09-29 2018-12-06 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
EP3363461A4 (de) 2015-10-12 2019-05-15 Aprogen Kic Inc. Anti-cd43-antikörper und verwendung davon zur krebsbehandlung
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
US11045547B2 (en) 2015-12-16 2021-06-29 Merck Sharp & Dohme Corp. Anti-LAG3 antibodies and antigen-binding fragments
BR112018015259A2 (pt) * 2016-01-27 2018-12-18 Medimmune Llc métodos para preparação de anticorpos com um padrão de glicosilação definido
CU24613B1 (es) 2016-02-06 2022-07-08 Epimab Biotherapeutics Inc Proteínas de unión a inmunoglobulinas fabs en tandem (fit-ig) biespecíficas que se unen a cmet y egfr
SG11201805941WA (en) 2016-02-17 2018-09-27 Novartis Ag Tgfbeta 2 antibodies
KR102438140B1 (ko) 2016-03-22 2022-08-31 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 인간화 항-클라우딘-1 항체 및 이의 용도
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
BR112018075630A2 (pt) 2016-06-08 2019-03-19 Abbvie Inc. anticorpos anti-cd98 e conjugados de fármaco de anticorpo
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
CN109562190A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗egfr抗体药物偶联物
WO2017214335A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
CN116173232A (zh) 2016-06-08 2023-05-30 艾伯维公司 抗cd98抗体及抗体药物偶联物
RU2018147224A (ru) 2016-06-08 2020-07-14 Эббви Инк. Конъюгаты антитела к egfr и лекарственного средства
AU2017277422A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-EGFR antibody drug conjugates
JP2019522643A (ja) 2016-06-08 2019-08-15 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
EP3478830B1 (de) 2016-07-01 2024-04-10 Resolve Therapeutics, LLC Optimierte binukleasefusionen und -verfahren
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
JP7219207B2 (ja) 2016-07-29 2023-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 腫瘍関連マクロファージを標的化する抗体及びその使用
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018026969A2 (en) 2016-08-03 2018-02-08 Achaogen, Inc. Plazomicin antibodies and methods of use
BR112019002579A2 (pt) 2016-08-16 2019-05-21 Epimab Biotherapeutics, Inc. anticorpos biespecíficos fab monovalentes, assimétricos e tandem
JP7174691B2 (ja) 2016-08-23 2022-11-17 メディミューン リミテッド 抗ｖｅｇｆ－ａおよび抗ａｎｇ２抗体ならびにそれらの使用
KR102538827B1 (ko) 2016-08-23 2023-05-31 메디뮨 리미티드 항-ｖｅｇｆ-ａ 항체 및 이의 용도
US20190270821A1 (en) 2016-09-13 2019-09-05 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
JP2019535306A (ja) 2016-10-25 2019-12-12 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル） Ｃｄ１６０膜貫通型アイソフォームと結合するモノクローナル抗体
US10899842B2 (en) 2016-11-23 2021-01-26 Immunoah Therapeutics, Inc. 4-1BB binding proteins and uses thereof
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
EP3579872A1 (de) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von krebs in verbindung mit aktivierung der mapk-leitungsbahn
JP2020510432A (ja) 2017-03-02 2020-04-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｎｅｃｔｉｎ−４への特異性を有する抗体及びその使用
WO2018170332A1 (en) * 2017-03-15 2018-09-20 Nutech Ventures Extracellular vesicles and methods of using
KR102628323B1 (ko) 2017-03-24 2024-01-22 노바르티스 아게 심장질환 예방 및 치료 방법
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
KR20190140454A (ko) 2017-04-13 2019-12-19 아두로 바이오테크 홀딩스, 유럽 비.브이. 항-sirp 알파 항체
CA3064697A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
CA3064333A1 (en) 2017-05-29 2018-12-06 Gamamabs Pharma Cancer-associated immunosuppression inhibitor
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
US11898187B2 (en) 2017-08-15 2024-02-13 Northwestern University Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases
CA3073537A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof
EP3672990A1 (de) 2017-08-25 2020-07-01 Five Prime Therapeutics, Inc. B7-h4-antikörper und verfahren zur verwendung davon
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
MX2020008730A (es) 2018-02-21 2020-12-07 Five Prime Therapeutics Inc Regímenes de dosificación de anticuerpo b7-h4.
CA3091174A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
SG11202008105RA (en) 2018-03-02 2020-09-29 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
EP3765499A1 (de) 2018-03-12 2021-01-20 Zoetis Services LLC Anti-ngf-antikörper und verfahren dafür
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
US11725224B2 (en) 2018-04-16 2023-08-15 Northwestern University Methods for co-activating in vitro non-standard amino acid (nsAA) incorporation and glycosylation in crude cell lysates
WO2020041483A1 (en) * 2018-08-21 2020-02-27 Clara Foods Co. Modification of protein glycosylation in microorganisms
TW202019480A (zh) 2018-09-13 2020-06-01 美國德州系統大學評議委員會 新穎lilrb4抗體及其用途
US20220073638A1 (en) 2018-09-19 2022-03-10 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
CN113166242A (zh) 2018-10-15 2021-07-23 戊瑞治疗有限公司 用于癌症的组合疗法
US20220025058A1 (en) 2018-11-06 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
US20220064260A1 (en) 2018-12-14 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
KR20210113261A (ko) 2019-01-04 2021-09-15 리졸브 테라퓨틱스, 엘엘씨 뉴클레아제 융합 단백질을 사용한 쇼그렌병의 치료
WO2020148207A1 (en) 2019-01-14 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies binding to hla-a2
JP2022538733A (ja) 2019-05-20 2022-09-06 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 新規抗ｃｄ２５抗体
UY38747A (es) 2019-06-12 2021-01-29 Novartis Ag Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
KR20220034848A (ko) 2019-07-11 2022-03-18 클라라 푸드즈 컴퍼니 단백질 조성물 및 이의 섭취 가능한 제품
EP3999540A1 (de) 2019-07-16 2022-05-25 Institut National de la Santé et de la Recherche Médicale (INSERM) Antikörper mit spezifizität für cd38 und verwendungen davon
US10927360B1 (en) 2019-08-07 2021-02-23 Clara Foods Co. Compositions comprising digestive enzymes
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
WO2021064184A1 (en) 2019-10-04 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
WO2021116119A1 (en) 2019-12-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
US20230091231A1 (en) 2020-01-21 2023-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Utilization of plant protein homologues in culture media
AU2021215936A1 (en) 2020-02-05 2022-08-25 Larimar Therapeutics, Inc. TAT peptide binding proteins and uses thereof
EP4132971A1 (de) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinitätsgereifte anti-lap-antikörper und verwendungen davon
EP4143227A2 (de) 2020-04-30 2023-03-08 Sairopa B.V. Anti-cd103 antikörper
WO2021228956A1 (en) 2020-05-12 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
CR20220646A (es) 2020-05-17 2023-10-23 Astrazeneca Uk Ltd Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos
US11702467B2 (en) 2020-06-25 2023-07-18 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
CA3165342A1 (en) 2020-06-29 2022-01-06 James Arthur Posada Treatment of sjogren's syndrome with nuclease fusion proteins
US20230323299A1 (en) 2020-08-03 2023-10-12 Inserm (Institut National De La Santé Et De La Recherch Médicale) Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
JP2023537078A (ja) 2020-08-10 2023-08-30 アストラゼネカ・ユーケイ・リミテッド ＣＯＶＩＤ－１９を治療及び防止するためのＳＡＲＳ－ＣｏＶ－２抗体
US20240002521A1 (en) 2020-11-20 2024-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
WO2022106665A1 (en) 2020-11-20 2022-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
KR20230129481A (ko) 2021-01-08 2023-09-08 베이징 한미 파마슈티컬 컴퍼니 리미티드 Cd47과 특이적으로 결합하는 항체 및 그 항원 결합단편
CN116710482A (zh) 2021-01-08 2023-09-05 北京韩美药品有限公司 特异性结合4-1bb的抗体及其抗原结合片段
WO2022148414A1 (zh) 2021-01-08 2022-07-14 北京韩美药品有限公司 特异性结合pd-l1的抗体及其抗原结合片段
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
EP4313317A1 (de) 2021-03-23 2024-02-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur diagnose und behandlung von t-zelllymphomen
EP4320153A1 (de) 2021-04-09 2024-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur behandlung von anaplastischem grosszelligem lymphom
CA3219360A1 (en) 2021-06-22 2022-12-29 Novartis Ag Bispecific antibodies for use in treatment of hidradenitis suppurativa
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
EP4186529A1 (de) 2021-11-25 2023-05-31 Veraxa Biotech GmbH Verbesserte antikörper-nutzlast-konjugate (aps), hergestellt durch ortsspezifische konjugation mittels genetischer codeerweiterung
WO2023094525A1 (en) 2021-11-25 2023-06-01 Veraxa Biotech Gmbh Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
WO2023110937A1 (en) 2021-12-14 2023-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023187657A1 (en) 2022-03-30 2023-10-05 Novartis Ag Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
WO2023198648A1 (en) 2022-04-11 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t-cell malignancies
WO2023198874A1 (en) 2022-04-15 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
CN115386009B (zh) * 2022-04-26 2023-12-01 江苏靶标生物医药研究所有限公司 一种膜联蛋白v与血管生成抑制剂融合蛋白的构建方法和应用
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins
WO2024003310A1 (en) 2022-06-30 2024-01-04 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of acute lymphoblastic leukemia
WO2024017998A1 (en) 2022-07-21 2024-01-25 Technische Universität Dresden M-csf for use in the prophylaxis and/or treatment of viral infections in states of immunosuppression
EP4309666A1 (de) 2022-07-21 2024-01-24 Technische Universität Dresden M-csf zur verwendung bei der prophylaxe und/oder behandlung viraler infektionen bei immunsuppressionszuständen
WO2024018046A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
CN115590017B (zh) * 2022-11-04 2023-09-12 中国农业大学 一种通过降低线粒体温度提高卵母细胞冷冻效果的方法

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US513854A (en) * 1894-01-30 Clevis
US4166329A (en) * 1978-10-10 1979-09-04 Herbig Charles A Adjustable arch support for shoes
US4414329A (en) 1980-01-15 1983-11-08 Phillips Petroleum Company Biochemical conversions by yeast fermentation at high cell densities
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4617274A (en) 1981-10-29 1986-10-14 Phillips Petroleum Company Biochemical conversions by yeast fermentation at high cell densities
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4655231A (en) * 1984-01-09 1987-04-07 Advanced Tobacco Products, Inc. Snuff and preparation thereof
US4885242A (en) 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4855231A (en) 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4808537A (en) 1984-10-30 1989-02-28 Phillips Petroleum Company Methanol inducible genes obtained from pichia and methods of use
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US5032516A (en) 1985-10-25 1991-07-16 Phillips Petroleum Company Pichia pastoris alcohol oxidase II regulatory region
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US5166329A (en) 1985-10-25 1992-11-24 Phillips Petroleum Company DNA encoding the alcohol oxidase 2 gene of yeast of the genus Pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US5837518A (en) * 1986-01-31 1998-11-17 Genetics Institute, Inc. Thrombolytic proteins
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5272066A (en) 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US4925796A (en) 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4857467A (en) 1986-07-23 1989-08-15 Phillips Petroleum Company Carbon and energy source markers for transformation of strains of the genes Pichia
US5002876A (en) 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4683293A (en) 1986-10-20 1987-07-28 Phillips Petroleum Company Purification of pichia produced lipophilic proteins
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5135854A (en) 1987-10-29 1992-08-04 Zymogenetics, Inc. Methods of regulating protein glycosylation
US4816700A (en) * 1987-12-16 1989-03-28 Intel Corporation Two-phase non-overlapping clock generator
US5004688A (en) 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5122465A (en) 1989-06-12 1992-06-16 Phillips Petroleum Company Strains of pichia pastoris created by interlocus recombination
US5032519A (en) 1989-10-24 1991-07-16 The Regents Of The Univ. Of California Method for producing secretable glycosyltransferases and other Golgi processing enzymes
US5324663A (en) 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5595900A (en) 1990-02-14 1997-01-21 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
DE4028800A1 (de) 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
US5962294A (en) 1992-03-09 1999-10-05 The Regents Of The University Of California Compositions and methods for the identification and synthesis of sialyltransferases
US5602003A (en) 1992-06-29 1997-02-11 University Of Georgia Research Foundation N-acetylglucosaminyltransferase V gene
EP0698103A1 (de) 1993-05-14 1996-02-28 PHARMACIA & UPJOHN COMPANY Klonierte DNS, die für eine UDP-GALNAC: Polypeptid, N - Acetyl-Galactosaminyltransferase kodiert
US5484590A (en) 1993-09-09 1996-01-16 La Jolla Cancer Research Foundation Expression of the developmental I antigen by a cloned human cDNA encoding a member of a β-1,6-N-acetylglucosaminyltransferase gene family
US6300113B1 (en) 1995-11-21 2001-10-09 New England Biolabs Inc. Isolation and composition of novel glycosidases
US5683899A (en) 1994-02-03 1997-11-04 University Of Hawaii Methods and compositions for combinatorial-based discovery of new multimeric molecules
US6069235A (en) 1994-02-23 2000-05-30 Monsanto Company Method for carbohydrate engineering of glycoproteins
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
CZ292061B6 (cs) * 1994-03-17 2003-07-16 Merck Patent Gmbh Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
AU2575395A (en) 1994-06-13 1996-01-05 Banyu Pharmaceutical Co., Ltd. Gene coding for glycosyltransferase and use thereof
US5545553A (en) 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6096743A (en) * 1994-09-27 2000-08-01 Yamanouchi Pharmaceuticals Co., Ltd. 1,2,3,4-tetrahydroquinoxalinedione derivative
DE4439759C1 (de) * 1994-11-07 1996-02-01 Siemens Ag Photodiodenarray
US5849904A (en) 1994-12-22 1998-12-15 Boehringer Mannheim Gmbh Isolated nucleic acid molecules which hybridize to polysialyl transferases
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
JP2810635B2 (ja) 1995-04-03 1998-10-15 理化学研究所 新規糖鎖合成酵素
JPH08336387A (ja) 1995-06-12 1996-12-24 Green Cross Corp:The ピキア属酵母由来の糖鎖伸長タンパク及びそのｄｎａ
CZ89098A3 (cs) * 1995-09-29 1998-09-16 Glycim Oy Syntetické polylaktosaminy obsahující až multivalentní sLEX a metody pro jejich použití
JP3348336B2 (ja) * 1995-10-26 2002-11-20 株式会社豊田中央研究所 吸着ヒートポンプ
US5910570A (en) 1995-11-13 1999-06-08 Pharmacia & Upjohn Company Cloned DNA encoding a UDP-GalNAc: polypeptide N-acetylgalactosaminy-ltransferase
EP0874900B1 (de) 1996-08-02 2007-10-03 The Austin Research Institute Verbesserte nukleinsäuren, welche für eine chimäre glycosyltransferase kodieren
US6338955B2 (en) 1996-12-12 2002-01-15 Kirin Beer Kabushiki Kaisha β1-4 N-acetylglucosaminyltransferase and gene encoding
US5945314A (en) 1997-03-31 1999-08-31 Abbott Laboratories Process for synthesizing oligosaccharides
US20040191256A1 (en) 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US7029870B1 (en) 1997-07-03 2006-04-18 Human Genome Sciences, Inc. Gabaa receptor epsilon subunits
HUP0003418A2 (hu) * 1997-09-05 2001-02-28 Glycim Oy Szintetikus, kétértékű, sLex-tartalmú polilaktózaminok és eljárás előállításukra
JPH11103158A (ja) 1997-09-26 1999-04-13 Olympus Optical Co Ltd プリント配線板へのフリップチップ実装方法および実装構造
US7244601B2 (en) 1997-12-15 2007-07-17 National Research Council Of Canada Fusion proteins for use in enzymatic synthesis of oligosaccharides
JPH11221079A (ja) 1998-02-04 1999-08-17 Kyowa Hakko Kogyo Co Ltd 糖転移酵素および該酵素をコードするｄｎａ
WO1999040208A1 (en) 1998-02-05 1999-08-12 The General Hospital Corporation In vivo construction of dna libraries
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6324663B1 (en) * 1998-10-22 2001-11-27 Vlsi Technology, Inc. System and method to test internal PCI agents
US6870565B1 (en) 1998-11-24 2005-03-22 Micron Technology, Inc. Semiconductor imaging sensor array devices with dual-port digital readout
ATE475714T1 (de) * 1998-12-09 2010-08-15 Phyton Holdings Llc Verfahren zur herstellung von glycoprotein mit menschlichem glycosylierungsbild
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
CA2382184A1 (en) * 1999-08-19 2001-03-01 Kirin Beer Kabushiki Kaisha Novel yeast mutants and process for producing glycoprotein containing mammalian type sugar chain
WO2001025406A1 (en) 1999-10-01 2001-04-12 University Of Victoria Innovation & Development Corporation Mannosidases and methods for using same
JP2003514541A (ja) 1999-11-19 2003-04-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １８個のヒト分泌タンパク質
AU2001241541A1 (en) 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
US6410246B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Highly diverse library of yeast expression vectors
US20060029604A1 (en) 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US20060024304A1 (en) 2000-06-28 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US8697394B2 (en) 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
EP2322644A1 (de) 2000-06-28 2011-05-18 GlycoFi, Inc. Verfahren für die Herstellung modifizierter Glykoproteine
US20060257399A1 (en) 2000-06-28 2006-11-16 Glycofi, Inc. Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
US20060034830A1 (en) 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US20060034828A1 (en) 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
JP4092194B2 (ja) * 2000-06-30 2008-05-28 フランダース インターユニバーシティ インスティテュート フォア バイオテクノロジー （ヴィーアイビー） ピキアパストリス（ＰｉｃｈｉａＰａｓｔｏｒｉｓ）におけるタンパク質糖鎖修飾
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JP4655388B2 (ja) 2001-03-05 2011-03-23 富士レビオ株式会社 タンパク質の生産方法
AU2002305903A1 (en) 2001-05-25 2002-12-09 Incyte Genomics Inc. Carbohydrate-associated proteins
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
GB0120311D0 (en) * 2001-08-21 2001-10-17 Immunoporation Ltd Treating cells
WO2003025148A2 (en) 2001-09-19 2003-03-27 Nuvelo, Inc. Novel nucleic acids and polypeptides
JP2005532253A (ja) 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
US20060024292A1 (en) 2001-12-27 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
US20060034829A1 (en) 2001-12-27 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
ES2402527T3 (es) 2001-12-27 2013-05-06 Glycofi, Inc. Procedimientos para obtener estructuras de carbohidrato de tipo mamífero mediante ingeniería genética
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US7514253B2 (en) 2003-05-16 2009-04-07 Glycofi, Inc. URA5 gene and methods for stable genetic integration in yeast
EP1633312A4 (de) * 2003-06-16 2012-09-26 Medimmune Llc Influenza-hämagglutinin- und neuraminidase-varianten
ES2528739T3 (es) 2003-12-24 2015-02-12 Glycofi, Inc. Métodos para eliminar la manosilfosforilación de glucanos en la producción de glucoproteínas
JP2007525146A (ja) 2003-12-30 2007-09-06 ガムリンク エー／エス 生分解性ポリマーを含み且つ分解性を促進させたチューインガム
WO2005090552A2 (en) 2004-03-17 2005-09-29 Glycofi, Inc. Method of engineering a cytidine monophosphate-sialic acid synthetic pathway in fungi and yeast
US20050265988A1 (en) 2004-03-18 2005-12-01 Byung-Kwon Choi Glycosylated glucocerebrosidase expression in fungal hosts
CN101084233B (zh) 2004-04-29 2012-08-15 格利科菲公司 用于在糖蛋白产生中减少或消除α-甘露糖苷酶抗性聚糖的方法
US7849651B2 (en) * 2005-05-31 2010-12-14 Kubota Matsushitadenko Exterior Works, Ltd. Wall materials bracket and insulating wall structure
JP2009507040A (ja) 2005-09-02 2009-02-19 グライコフィ， インコーポレイテッド 主としてｇｌｃｎａｃｍａｎ３ｇｌｃｎａｃ２糖形態を含む免疫グロブリン
AU2006316838B2 (en) * 2005-11-15 2012-04-12 Glycofi, Inc Production of glycoproteins with reduced O-glycosylation
US20080274162A1 (en) * 2007-05-04 2008-11-06 Jeffrey Nessa Method, composition, and delivery mode for treatment of prostatitis and other urogenital infections using a probiotic rectal suppository
TW201028431A (en) * 2008-10-31 2010-08-01 Lonza Ag Novel tools for the production of glycosylated proteins in host cells
JP2011039027A (ja) * 2009-07-14 2011-02-24 Pacific Ind Co Ltd 金属調樹脂カバー及びその製造方法並びに車両用ドアハンドル
US9439972B2 (en) * 2012-09-10 2016-09-13 Ad Lunam Labs, Inc. Antifungal serum

Also Published As

Publication number Publication date
DK1522590T3 (da) 2009-12-21
PT1522590E (pt) 2009-10-26
US20110020870A1 (en) 2011-01-27
EP2339013A1 (de) 2011-06-29
EP2119793A1 (de) 2009-11-18
US20080274498A1 (en) 2008-11-06
US7629163B2 (en) 2009-12-08
JP2011167194A (ja) 2011-09-01
US20100021991A1 (en) 2010-01-28
EP1522590A1 (de) 2005-04-13
DE60139720D1 (de) 2009-10-08
NZ523476A (en) 2004-04-30
WO2002000879A2 (en) 2002-01-03
US7326681B2 (en) 2008-02-05
US7981660B2 (en) 2011-07-19
US20140234902A1 (en) 2014-08-21
US20160068880A1 (en) 2016-03-10
EP1297172B1 (de) 2005-11-09
US20020137134A1 (en) 2002-09-26
ES2330330T3 (es) 2009-12-09
CA2412701A1 (en) 2002-01-03
ATE440959T1 (de) 2009-09-15
JP2004501642A (ja) 2004-01-22
US20130295604A1 (en) 2013-11-07
US7029872B2 (en) 2006-04-18
US20060177898A1 (en) 2006-08-10
CY1109639T1 (el) 2014-08-13
MXPA03000105A (es) 2004-09-13
WO2002000879A3 (en) 2002-09-06
US20120322100A1 (en) 2012-12-20
US8211691B2 (en) 2012-07-03
KR100787073B1 (ko) 2007-12-21
US20070105127A1 (en) 2007-05-10
EP2322644A1 (de) 2011-05-18
EP1522590B1 (de) 2009-08-26
KR20030031503A (ko) 2003-04-21
AU7684201A (en) 2002-01-08
US20060078963A1 (en) 2006-04-13
US20070178551A1 (en) 2007-08-02
ATE309385T1 (de) 2005-11-15
ES2252261T3 (es) 2006-05-16
EP2339013B1 (de) 2014-07-02
EP1297172A2 (de) 2003-04-02
US20060148035A1 (en) 2006-07-06
DK1297172T3 (da) 2006-02-13
AU2001276842B2 (en) 2007-04-26
US7923430B2 (en) 2011-04-12
DE60114830T2 (de) 2006-08-03

Similar Documents

Publication Publication Date Title
DE60114830D1 (de) Verfahren für die herstellung modifizierter glykoproteine
WO2007087420A3 (en) Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
DE602004024649D1 (de) Produktion modifizierter glykoproteine mit mehrfach verzweigten strukturen
Montero-Morales et al. Advanced plant-based glycan engineering
MXPA04006357A (es) Metodos para disenar estructuras de carbohidrato del tipo de mamifero.
MX2008000200A (es) Polinucleotidos que codifican enzimas que modifican el isoprenoide y sus metodos de uso.
DE602004025206D1 (de) Expression von klasse ii mannosidase und klasse iii mannosidase in zellen niederer eukaryoten
ATE469236T1 (de) Kombinatorische dna-bibliothek zur herstellung modifizierter n-glukane in niederen eukaryoten
AU2003210405A1 (en) Inbred embryonic stem-cell derived mice
WO2005095617A3 (en) Plants with increased activity of a starch phosphorylating enzyme
EP0952224A3 (de) Verfahren zur Herstellung transgener Gurken mit hohem Superoxid-dismutasegehalt
WO2006096050A3 (en) Glycoengineering in mushrooms
Sano et al. Thiamine pyrophosphatase and nucleoside diphosphatase in rat brain
CA2230975A1 (en) Wheat aleurone promoter
BR0209727A (pt) Microorganismo de tipo alimentar geneticamente modificado, processos para produzir folato de monoglutamila e para suprir folato biodisponìvel ao trato gastrointestinal de um mamìfero, e, produto alimentìcio
WO2023049786A3 (en) Yeast cells with improved tolerance to acrylic acid
WO2023049789A3 (en) Yeast cells with reduced propensity to degrade acrylic acid
Weidanz Hexosamine metabolism in the human malaria parasite Plasmodium falciparum.
WO2001049856A3 (en) Drosophila enzymes, encoding nucleic acids and methods of use
WO2004003208A3 (en) Stress tolerant plant
TH68812A (th) การเตรียมโปรตีนแอนตี้ฟรีซ
TH63314B (th) การเตรียมโปรตีนแอนตี้ฟรีซ
TH75075A (th) ไซลาเนสที่แสดงออกโดยจุลินทรีย์ และการใช้ของมันเป็นสารเติมแต่งอาหารสัตว์และการใช้อื่นๆ

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation